Premium
Antiarrhythmic Effect of Delta 2 ‐Specific Opioid Receptor Agonist During Ischemia and Reperfusion of Hearts In Vivo
Author(s) -
Oeltgen Peter R,
Maslov Leonid N,
Govindaswami Meera,
Brown Stephen A
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a321-d
Subject(s) - medicine , ischemia , ventricular fibrillation , agonist , anesthesia , saline , ventricular tachycardia , cardiology , in vivo , receptor , biology , microbiology and biotechnology
The effects of δ 2 – opioid receptor stimulation on 45 min ischemia (first ischemia 10 min followed by second ischemia 35 min) and 10 min reperfusion‐induced arrhythmias were investigated by I.V. administration of a new δ 2 selective agonist. ZGI‐07 was infused at aconcentration of 0.23 mg/kg into ketamine anesthetized male Wistar rats weighing 220–250g 15 min before coronary artery occlusion. Control rats (n=16) were infused with physiological saline 0.9%. Significantly (p=<0.05) increased number of ZGI‐07 rats (n=15) were without arrhythmias in both ischemic periods.53% (8 out of 15) rats for both the first and second ischemic periods were without arrhythmias versus 13% (2 out of 16) for controls for both periods of ischemia. ZGI‐07 treated rats had significantly (p=<0.05) decreased ventricular ectopic beats for first ischemic period (40%) and second ischemic period (33%) versus controls which had 81% and 75% incidence. Only 27% of ZGI‐07 treated rats had ventricular tachycardia for both periods (p=<0.01) versus controls which had 81% and 69% incidence. No ZGI‐07 rats exhibited ventricular fibrillation during ischemic period one and only one animal (7%) during ischemic period two versus controls 31% during period one and 25% during period two. No significant differences in arrhythmic incidence between ZGI‐07 and controls were noted during the 10 min reperfusion period. These data suggest that the δ 2 receptor plays a role in the regulation of cardiac tolerance to both short and long term ischemia. (Supported in part by Office of Naval Research award N00014‐01‐1‐0404).